Patents by Inventor Jean-Olivier Zirimwabagabo

Jean-Olivier Zirimwabagabo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS
    Publication number: 20230036854
    Abstract: Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: wherein R1, R2, R4, R5, R6, R7, R8, R9, R10, Z, X1, X2, X3, L2, HET, n and q are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.
    Type: Application
    Filed: November 15, 2019
    Publication date: February 2, 2023
    Inventors: Gareth RICHARDS, Timothy M. SKERRY, Joseph P.A. HARRITY, Jean-Olivier ZIRIMWABAGABO, Matthew J. TOZER, Karl Richard GIBSON, Roderick Alan PORTER, Paul Alan GLOSSOP
  • Compounds
    Patent number: 11400081
    Abstract: Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein R1, R2, R3, R4, R5, R6, R8, R9, X, X1, X2, X3, L1 and n are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: August 2, 2022
    Assignee: The University of Sheffield
    Inventors: Gareth Richards, Timothy M. Skerry, Joseph P. A. Harrity, Jean-Olivier Zirimwabagabo, Matthew J. Tozer, Karl Richard Gibson, Roderick Alan Porter, Paul Matthew Blaney, Paul Alan Glossop
  • HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS
    Publication number: 20220023281
    Abstract: Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: wherein HET, R1, R2, R3, R4, R5, L, L1, X1, X2, X3 and q are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.
    Type: Application
    Filed: November 15, 2019
    Publication date: January 27, 2022
    Inventors: Gareth RICHARDS, Timothy M. SKERRY, Joseph P.A. HARRITY, Jean-Olivier ZIRIMWABAGABO, Matthew J. TOZER, Karl Richard GIBSON, Roderick Alan PORTER, Paul Alan GLOSSOP
  • COMPOUNDS
    Publication number: 20210113534
    Abstract: Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein R1, R2, R3, R4, R5, R6, R8, R9, X, X1, X2, X3, L1 and n are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.
    Type: Application
    Filed: May 16, 2018
    Publication date: April 22, 2021
    Inventors: Gareth Richards, Timothy M. Skerry, Joseph P.A. Harrity, Jean-Olivier Zirimwabagabo, Matthew J. Tozer, Karl Richard Gibson, Roderick Alan Porter, Paul Matthew Blaney, Paul Alan Glossop